凝血酶原复合物治疗创伤性凝血病:系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE和EMBASE数据库,纳入9项观察性研究和1项随机对照试验,共1150例接受凝血酶原复合物的成人严重创伤患者。大多数研究使用四因子凝血酶原复合物,剂量为20-30 U/kg。8项报告死亡率的观察性研究汇总OR为0.97(95%CI 0.56-1.69),5项报告深静脉血栓的观察性研究汇总OR为0.83(95%CI 0.44-1.57);合并观察性研究与随机对照试验后,死亡率和深静脉血栓的OR分别为0.94(95%CI 0.60-1.45)和1.00(95%CI 0.64-1.55)。结论认为凝血酶原复合物未显著降低死亡率,也未增加静脉血栓栓塞风险,但潜在血栓风险仍是未来研究需关注的问题。
要点
- 在成人严重创伤患者中,凝血酶原复合物未显著降低死亡率:8项观察性研究汇总OR 0.97(95%CI 0.56-1.69),合并随机对照试验后OR 0.94(95%CI 0.60-1.45)。
- 凝血酶原复合物未显著增加深静脉血栓风险:5项观察性研究汇总OR 0.83(95%CI 0.44-1.57),合并随机对照试验后OR 1.00(95%CI 0.64-1.55)。
- 大多数研究使用四因子凝血酶原复合物,剂量为20-30 U/kg;观察性研究中的联合干预包括全血(n=1)、纤维蛋白原浓缩物(n=2)或新鲜冰冻血浆(n=4)。
- 各研究结局报告不一致,测量指标和时间点差异较大;潜在血栓风险仍是未来研究需关注的问题。
适用人群与场景
- 成人严重创伤患者,用于治疗创伤性凝血病(可单独使用或与其他治疗联合)。
- 排除:儿科患者、仅创伤性脑损伤的研究、仅抗凝患者的研究。
处置流程与药物剂量
- 大多数研究使用四因子凝血酶原复合物,剂量为20-30 U/kg。
- 观察性研究中的联合干预包括全血(n=1)、纤维蛋白原浓缩物(n=2)或新鲜冰冻血浆(n=4)。
研究设计与关键结果
- 系统评价与荟萃分析,纳入9项观察性研究和1项随机对照试验,共1150例接受凝血酶原复合物的患者。
- 8项观察性研究汇总死亡率OR为0.97(95%CI 0.56-1.69);5项观察性研究汇总深静脉血栓OR为0.83(95%CI 0.44-1.57)。
- 合并观察性研究与随机对照试验后,死亡率OR为0.94(95%CI 0.60-1.45),深静脉血栓OR为1.00(95%CI 0.64-1.55)。
- 各研究结局报告不一致,测量指标和时间点差异较大。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入观察性研究和随机对照试验;使用GRADE评估证据质量。
- 局限:各研究结局报告不一致,测量指标和时间点差异较大;潜在血栓风险仍是未来研究需关注的问题。
对床旁实践的改变
- 原文结论认为凝血酶原复合物未显著降低死亡率,也未增加静脉血栓栓塞风险,但潜在血栓风险仍是未来研究需关注的问题。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma-induced coagulopathy (TIC) is common in trauma patients with major hemorrhage. Prothrombin complex concentrate (PCC) is used as a potential treatment for the correction of TIC, but the efficacy, timing, and evidence to support its use in injured patients with hemorrhage are unclear.
METHODS: A systematic search of published studies was performed on MEDLINE and EMBASE databases using standardized search equations. Ongoing studies were identified using clinicaltrials.gov. Studies investigating the use of PCC to treat TIC (on its own or in combination with other treatments) in adult major trauma patients were included. Studies involving pediatric patients, studies of only traumatic brain injury (TBI), and studies involving only anticoagulated patients were excluded. Primary outcomes were in-hospital mortality and venous thromboembolism (VTE). Pooled effects of PCC use were reported using random-effects model meta-analyses. Risk of bias was assessed for each study, and we used the Grading of Recommendations Assessment, Development, and Evaluation to assess the quality of evidence.
RESULTS: After removing duplicates, 1745 reports were screened and nine observational studies and one randomized controlled trial (RCT) were included, with a total of 1150 patients receiving PCC. Most studies used 4-factor-PCC with a dose of 20-30U/Kg. Among observational studies, co-interventions included whole blood (n = 1), fibrinogen concentrate (n = 2), or fresh frozen plasma (n = 4). Outcomes were inconsistently reported across studies with wide variation in both measurements and time points. The eight observational studies included reported mortality with a pooled odds ratio of 0.97 [95% CI 0.56-1.69], and five reported deep venous thrombosis (DVT) with a pooled OR of 0.83 [95% CI 0.44-1.57]. When pooling the observational studies and the RCT, the OR for mortality and DVT was 0.94 [95% CI 0.60-1.45] and 1.00 [95% CI 0.64-1.55] respectively.
CONCLUSIONS: Among published studies of TIC, PCCs did not significantly reduce mortality, nor did they increase the risk of VTE. However, the potential thrombotic risk remains a concern that should be addressed in future studies. Several RCTs are currently ongoing to further explore the efficacy and safety of PCC.
参考来源
- Hannadjas I, James A, Davenport R, et al. Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses. Crit Care. 2023. PMID: 37919775. doi:10.1186/s13054-023-04688-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。